Investegate |Syncona Limited Announcements | Syncona Limited: Achilles reports Q1 2022 Financial Results
Investegate announcements from Syncona Limited, Achilles reports Q1 2022 Financial Results
Stay updated with breaking news from Tumor Archiving Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from Syncona Limited, Achilles reports Q1 2022 Financial Results
- Patient data from higher dose cNeT as monotherapy and cNeT in combination with checkpoint inhibitor expected in 2H 2022 - - Strong cash position of $266 million supports clinical development and
Investegate announcements from Syncona Limited, Achilles reports Full Year 2021 Results
Investegate announcements from Achilles Therapeutics PLC, Achilles Therapeutics Provides Business Update and Outlook for 2022
LONDON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announces